Biotech Values

[pcrutch]

Brean Murray Carret & Co. maintains a 'Buy' on InterMune Inc. (ITMN); German Consultant and
Confidence in Esbriet Pricing; PT $42

[ if pps above $20 tomorrow happens, i'm taking a vacation... ]

Analyst, Brian Skorney, said, "We reviewed the macro dynamics leading to the change in German pharmaceutical pricing and reimbursement, the ongoing impact of these changes to the therapeutics sector as a whole and Esbriet specifically with a highly recommend expert on German strategic market access. His indication that the GBA will likely ignore the negative IQWiG assessment and recommend that Esbriet price negotiations move forward but not quantify any benefit should provide some relief as the worst case scenario is less likely to play out. Based on our conversation with him, we increasingly believe that all parties involved want to ensure that Esbriet will be made available to German IPF patients and that our pricing expectations remain reasonable."